RxDoctor Payments Data

Carol Berry

Family · Florence, SCNPI 1497755052

Payments from drug & device makers

$3,295in general payments, 2019–2025

Across 153 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$1K
  • Scilex Pharmaceuticals Inc.$594
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$354
  • Collegium Pharmaceutical, Inc.$222
  • Virtus Pharmaceuticals LLC$188
  • Novo Nordisk$178
  • plus $603 from 15 others

What the payments were for

  • Food & beverage$3,27499%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,295 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,594
Medicare patients
171
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl399$302,027
Buprenorphine317$79,450
Lidocaine204$17,630
Buprenorphine Hcl717$13,021
Diclofenac Sodium193$11,377
Gabapentin618$6,929
ZtlidoLidocaine16$5,818
Ondansetron Hcl501$4,092
Pregabalin226$3,979
Naloxone Hcl36$2,097
Celecoxib178$1,900
Duloxetine Hcl187$1,792
Tizanidine Hcl284$1,721
Ibuprofen57$449
Ondansetron OdtOndansetron24$439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$222$302,027399 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl$114$92,4711,034 claims
Scilex Pharmaceuticals Inc.Ztlido$594$5,81816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →